Genentech: Brent McKenzie | Associate Director , Translational Immunology

A link to this page has been copied to your clipboard.

https://www.gene.com/scientists/our-scientists/brent-mckenzie

Paste this link in an email to share.

Ok

Scientists / Our Scientists

"In gRED we share a passion to translate the biggest scientific advances of today into the best possible drugs of tomorrow."

Years at Genentech

Awards & Honors

I joined gRED in 2014 to lead the Translational Immunology department and find the research environment at Genentech incredibly rewarding. I enjoy the challenge of working across multiple areas of unmet medical need alongside some of the best and brightest scientists. I was drawn to industry research early in my career through a fruitful collaboration as a PhD student in the Autoimmunity and Transplantation department at the Walter and Eliza Hall Institute (WEHI). After a postdoc I moved from WEHI to DNAX in Palo Alto California (now Merck) to further my experience in early stage drug discovery. There we performed pioneering work on cytokine and T cell biology that underpins several new drug targets still being pursued today. I then joined CSL ltd in Parkville Australia where I continued to employ numerous in-vivo models to understand cellular and subcellular mechanisms of Autoimmunity, Inflammation, Fibrosis, Coagulation, Cancer, Metabolism & Vaccine responses.

Featured Publication

RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.

Cell Death Differ. 2016 Sep 1;23(9):1565-76.

Newton K, Dugger DL, Maltzman A, Greve JM, Hedehus M, Martin-McNulty B, Carano RA, Cao TC, van Bruggen N, Bernstein L, Lee WP, Wu X, DeVoss J, Zhang J, Jeet S, Peng I, McKenzie BS, Roose-Girma M, Caplazi P, Diehl L, Webster JD, Vucic D.

View Abstract

Here in the Translational Immunology Department we use cutting edge methods and technologies to understand how molecular and cellular pathways contribute to disease pathogenesis in inflammatory, fibrotic, infectious and ocular diseases. We use in-vivo modeling to test new hypotheses, evaluate efficacy, understand drug safety and benchmark new therapies. We work on both early as well as late stage drug targets throughout our small and large molecule portfolio and enjoy collaborations with almost every other department here in gRED.

WEHI, PhD in Medical Biology – 2003
University of Melbourne, BSc. Hons. – 1998

University of Melbourne Honorable Appointment –
Hajime Research Award –
Australian Postgraduate Award –

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page.

Brent McKenzie

Associate Director , Translational Immunology

Featured Publication

RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page.

A link to this page has been copied to your clipboard.

Brent McKenzie

Associate Director , Translational Immunology

Featured Publication

RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.